^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

GEF-H1 activator

Related drugs:
Phase 2
Peking Union Medical College Hospital
Active, not recruiting
Last update posted :
02/18/2025
Initiation :
02/01/2023
Primary completion :
01/21/2025
Completion :
12/31/2025
EGFR • ALK • ROS1
|
Keytruda (pembrolizumab) • docetaxel • plinabulin (BPI 2358)
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/14/2024
Initiation :
04/14/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/03/2023
Initiation :
12/21/2021
Primary completion :
11/01/2025
Completion :
11/01/2025
CD34
|
plinabulin (BPI 2358) • Neulasta (pegfilgrastim)
Phase 3
BeyondSpring Pharmaceuticals Inc.
Completed
Last update posted :
09/10/2022
Initiation :
12/01/2015
Primary completion :
03/23/2021
Completion :
05/23/2021
EGFR • ALK
|
EGFR L858R • EGFR exon 19 deletion • ALK rearrangement
|
docetaxel • dexamethasone • plinabulin (BPI 2358)